The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Response to MM therapy can vary based on a variety of factors
The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden, Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, explains why an immediate and strong response to therapy isn’t always the best outcome to hope for, and mentions the factors that can have an impact on the efficacy of some drugs, from the biology of the disease to patient fitness.
